DOMO climbed about 17.2% over the trailing 30 days, rising from a July 15 adjusted close of $3.34 to roughly $3.92 in mid-August 2026. The advance was driven by Domo's agreement to sell substantially all operating assets and certain liabilities to Progress Software (PRGS) for $400 million in cash.
Tradr 2X Long SNDK Daily ETF (SNXX) declined approximately 55% over the past 30 days, reflecting a sharp selloff in the underlying Sandisk Corp. ( SNDK ) shares compounded by the fund's 2x daily leveraged structure. Over the broader quarter, SNXX exhibited extreme volatility, rallying to a peak near $46 before collapsing to the mid-teens, driven by both the parabolic rise and subsequent sharp correction in NAND flash memory equities.
USO surged approximately 26% over the last 30 days, driven by a sharp escalation in the US-Iran military conflict and renewed threats to critical oil transit chokepoints. Over the last quarter, the ETF has been roughly flat but extraordinarily volatile, collapsing below $104 in early July before rebounding dramatically.
SCHD tracks the Dow Jones U.S. Dividend 100 Index, holding approximately 103 dividend-paying U.S. companies through a rules-based quality, yield, and dividend-growth screen. The ETF's latest 30-day price move was roughly +6.7%, a steady advance that remained below the threshold for high-momentum or high-volatility positioning.
SLV rose approximately 16.1% over the latest 30-day window, moving from $50.39 to $58.48 at its most recent available close. The broader three-month trend remains negative, with SLV down roughly 15.3% from about three months earlier.
The iShares Russell 2000 ETF (IWM) tracks the Russell 2000 Index, spanning roughly 2,000 U.S. small-capitalization stocks. As of mid-August 2026, IWM traded near $305, up about 3.2% over the latest 30-calendar-day window and approximately 7.3% over the trailing quarter.
SOXL closed Friday's regular session down -0.28% at $144.95, versus $145.36 on Thursday; the move occurred during market hours, not premarket or after-hours. The dip reflected consolidation and modest profit-taking in semiconductor shares after SOXL had surged more than +25% from its late-July low through Aug. 13.
GLD closed Friday's regular session at $401.48, up +0.63% (+$2.52) from the prior session's $398.96 close; the move occurred entirely during regular market hours. Spot gold rose +0.7% to about $4,379/oz, supported by a -0.3% to -0.4% slide in the U.S. dollar index.
Destiny Tech100 Inc. (DXYZ) rose approximately 17.9% over the last 30 days, moving from a closing price near $27.15 to $32.00 in the latest completed session. The fund remains about 33% lower over the trailing three-month window, underscoring a volatile stretch that included a sharp run-up into the SpaceX public debut and a subsequent sell-off.
SPY fell -0.20% (-1.54 points) in Friday's regular session to close at 776.34, down from Thursday's 777.88 close; no further trading occurred Saturday. The move was driven by July U.S. retail sales, which fell -0.6% m/m versus +0.1% expected — the first monthly decline since October 2025.
Invesco QQQ Trust, Series 1 (QQQ) is a passively managed exchange-traded fund (ETF) that tracks the Nasdaq-100 Index, with roughly 105 holdings and about $490 billion in assets under management (AUM). The latest available close was $731.07, up about 1.9% from the close 30 calendar days earlier and approximately 1.6% over the trailing three months.
FAC traded down -9.57% at $5.20 during regular trading on Aug. 14, a -$0.55 move from the prior close of $5.75. Premarket action was only modestly lower near -0.87%, so the bulk of the selling emerged after the open and intensified into midday.
BLSH is trading down -10.55% at $24.58 during Friday's regular session, versus a previous close of $27.48. The slide follows Rosenblatt Securities cutting its BLSH price target to $30 from $42.50 while keeping a Neutral rating, citing weak third-quarter trading activity and likely downward consensus revisions.
IMC is down -22.43% at $7.84 during regular trading, reversing from a $10.10 prior close and a $9.80 open. The decline follows the prior session’s +26.25% surge to a 52-week high of $11.10, triggering sharp profit-taking.
Target in focus: Strategy Inc. (NASDAQ: MSTR ) currently trades near $92, and investors are asking whether the stock can reclaim the $200 level — a psychologically significant round number it last touched in May 2026. Strongest bullish factor: Strategy holds over 843,000 Bitcoin (BTC), making it the world's largest corporate BTC holder. Any sustained Bitcoin rally would directly lift the value of its treasury and likely drive the stock higher.
INO is up +13.33% during Friday’s regular session, trading near $1.02 versus Thursday’s close of $0.90. The move is primarily a continuation of Thursday’s post-earnings, analyst-upgrade momentum rather than a fresh company-specific headline.
The central question is whether Xencor, Inc. ( XNCR ) can reach a $30 stock price target , roughly 30% above recent trading near $23. The strongest bullish factor is operational momentum: second-quarter results beat expectations by a wide margin, and several clinical catalysts are approaching.
Xencor’s XmAb protein engineering platform positions the company for potential advances in bispecific antibody therapies targeting cancer and autoimmune diseases, with multiple programs in clinical development. Upcoming clinical data readouts and regulatory milestones for candidates such as XmAb942 in inflammatory bowel disease (IBD) represent key near-term catalysts that could influence investor sentiment.
XNCR advanced approximately 50.2% in the 30-day period, rising from a $14.98 close on July 15, 2026, to roughly $22.50 in mid-August. The move accelerated after Xencor announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma was selected for an oral presentation at ESMO 2026.
INO is trading up +2.42% at $0.9219 during regular market hours as of roughly 10:09 a.m. ET, compared with Thursday’s close of $0.9001. The advance extends Thursday’s +16.90% jump after Jefferies upgraded Inovio to Buy from Hold and raised its price target to $3.00 from $1.80 on positive FDA review progress for INO-3107.